181 related articles for article (PubMed ID: 34117917)
1. Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer.
Yaghoubi A; Asgharzadeh F; Movaqar A; Ghazvini K; Hassanian SM; Avan A; Khazaei M; Soleimanpour S
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2851-2865. PubMed ID: 34117917
[TBL] [Abstract][Full Text] [Related]
2. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
5. TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy.
Hao X; Yan Q; Zhao J; Wang W; Huang Y; Chen Y
PLoS One; 2015; 10(9):e0138911. PubMed ID: 26405806
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg3 enhances the anticancer effect of 5‑FU in colon cancer cells via the PI3K/AKT pathway.
Hong S; Cai W; Huang Z; Wang Y; Mi X; Huang Y; Lin Z; Chen X
Oncol Rep; 2020 Oct; 44(4):1333-1342. PubMed ID: 32945504
[TBL] [Abstract][Full Text] [Related]
7. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.
Ghosh S; Singh R; Vanwinkle ZM; Guo H; Vemula PK; Goel A; Haribabu B; Jala VR
Theranostics; 2022; 12(12):5574-5595. PubMed ID: 35910798
[TBL] [Abstract][Full Text] [Related]
8. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.
Touil Y; Igoudjil W; Corvaisier M; Dessein AF; Vandomme J; Monté D; Stechly L; Skrypek N; Langlois C; Grard G; Millet G; Leteurtre E; Dumont P; Truant S; Pruvot FR; Hebbar M; Fan F; Ellis LM; Formstecher P; Van Seuningen I; Gespach C; Polakowska R; Huet G
Clin Cancer Res; 2014 Feb; 20(4):837-46. PubMed ID: 24323901
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M
Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362
[TBL] [Abstract][Full Text] [Related]
10. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
11. Synergistic therapeutic effects of Schiff's base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model.
Wu X; He C; Wu Y; Chen X
Biomaterials; 2016 Jan; 75():148-162. PubMed ID: 26497429
[TBL] [Abstract][Full Text] [Related]
12. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH
Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570
[TBL] [Abstract][Full Text] [Related]
13. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro.
Shimoyama S; Mochizuki Y; Kusada O; Kaminishi M
Int J Oncol; 2002 Sep; 21(3):643-8. PubMed ID: 12168112
[TBL] [Abstract][Full Text] [Related]
14. The effects of 5-fluorouracil on the proteome of colon cancer cells.
Marin-Vicente C; Lyutvinskiy Y; Romans Fuertes P; Zubarev RA; Visa N
J Proteome Res; 2013 Apr; 12(4):1969-79. PubMed ID: 23477467
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1.
Hu C; Chen X; Huang Y; Chen Y
Apoptosis; 2018 Feb; 23(2):132-142. PubMed ID: 29397453
[TBL] [Abstract][Full Text] [Related]
16. Annexin A1 is involved in resistance to 5-FU in colon cancer cells.
Onozawa H; Saito M; Saito K; Kanke Y; Watanabe Y; Hayase S; Sakamoto W; Ishigame T; Momma T; Ohki S; Takenoshita S
Oncol Rep; 2017 Jan; 37(1):235-240. PubMed ID: 27840982
[TBL] [Abstract][Full Text] [Related]
17. Conditioned media from human macrophages of M1 phenotype attenuate the cytotoxic effect of 5‑fluorouracil on the HT‑29 colon cancer cell line.
Hedbrant A; Erlandsson A; Delbro D; Wijkander J
Int J Oncol; 2015 Jan; 46(1):37-46. PubMed ID: 25310018
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity.
Hao W; Hu C; Huang Y; Chen Y
PLoS One; 2019; 14(11):e0223738. PubMed ID: 31703065
[TBL] [Abstract][Full Text] [Related]
19. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of
Yaghoubi A; Movaqar A; Asgharzadeh F; Derakhshan M; Ghazvini K; Hasanian SM; Avan A; Mostafapour A; Khazaei M; Soleimanpour S
Iran J Basic Med Sci; 2023; 26(7):768-776. PubMed ID: 37396945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
